Get the Stockscreener App
2.59
4.44%
0.11
Insight Molecular Diagnostics Inc stock is traded at $2.59, with a volume of 23,169.
It is up +4.44% in the last 24 hours and down -8.80% over the past month.
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx.
See More
Previous Close:
$2.48
Open:
$2.48
24h Volume:
23,169
Relative Volume:
1.48
Market Cap:
$74.13M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+7.92%
1M Performance:
-8.80%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$2.48
$2.62
1-Week Range:
$2.35
$2.91
52-Week Range:
$2.33
$3.09
Insight Molecular Diagnostics Inc Stock (IMDX) Company Profile
Name
Insight Molecular Diagnostics Inc
Sector
Industry
Phone
949-409-7600
Address
2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE
Compare IMDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMDX
Insight Molecular Diagnostics Inc
|
2.59 | 76.41M | 0 | 0 | 0 | 0.00 |
|
TMO
Thermo Fisher Scientific Inc
|
499.99 | 184.10B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
211.80 | 149.66B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
645.55 | 51.03B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
121.63 | 33.56B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
191.15 | 32.73B | 15.70B | 1.24B | 2.01B | 6.91 |
Insight Molecular Diagnostics Inc Stock (IMDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-28-25 | Initiated | Lake Street | Buy |
| May-24-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Mar-14-22 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Mar-17-21 | Resumed | Needham | Buy |
| Jan-07-21 | Upgrade | The Benchmark Company | Speculative Buy → Buy |
| Dec-16-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-30-20 | Initiated | BTIG Research | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Jul-30-20 | Reiterated | The Benchmark Company | Speculative Buy |
| Jul-01-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-30-20 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jun-02-20 | Initiated | Needham | Buy |
| Feb-13-19 | Initiated | Piper Jaffray | Overweight |
| Jan-29-19 | Upgrade | Janney | Neutral → Buy |
| Dec-19-18 | Resumed | Lake Street | Buy |
View All
Insight Molecular Diagnostics Inc Stock (IMDX) Latest News
Insight Molecular Diagnostics: Pioneering the Next Generation of Transplant Rejection Testing and FDA Readiness - AInvest
Veterinary Molecular Diagnostics Market on Track for Massive Expansion by 2035, Forecasts Reveal. - newstrail.com
Analysts Offer Insights on Healthcare Companies: Immatics (IMTX) and Insight Molecular Diagnostics (IMDX) - The Globe and Mail
Insight Molecular Diagnostics Inc. shares rise 12.92% intraday after Myriad Genetics appoints new CFO. - AInvest
Insight Molecular: Needham Reiterates Buy Rating with $4.25 PT - AInvest
Insight Molecular Diagnostics: Paving the Next Frontier in Transplant Rejection Testing with FDA-Ready Innovation - AInvest
IMDX’s GraftAssureDx Study: A Game-Changer in Kidney Transplant Monitoring? - TipRanks
Insight Molecular Diagnostics Inc. shares rise 1.21% intraday after Caris Life Sciences validates MI Cancer Seek® assay. - AInvest
Insight Molecular Diagnostics Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - simplywall.st
Insight Molecular Diagnostics : With Q&A (insight molecular diagnostics inc imdx us q2 2025 earnings call 11 august 2025 5 00 pm et) - MarketScreener
Lake Street Sticks to Their Buy Rating for Insight Molecular Diagnostics (IMDX) - The Globe and Mail
Insight Molecular Diagnostics Inc. shares fall 1.53% intraday after reporting a Q2 loss of $9.7 million. - AInvest
Insight Molecular Diagnostics Inc (IMDX) Q2 2025 Earnings Call Highlights: Strategic Advances ... - Yahoo Finance
Needham reiterates Buy rating on Insight Molecular Diagnostics stock By Investing.com - Investing.com Nigeria
Needham reiterates Buy rating on Insight Molecular Diagnostics stock - Investing.com India
Insight Molecular Diagnostics: Promising Future with GraftAssureIQ and Strategic Expansion - TipRanks
Insight Molecular Diagnostics: Q2 Earnings Snapshot - Connecticut Post
Insight Molecular Diagnostics Reports Q2 2025 Progress - TipRanks
IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch - Santé log
Earnings call transcript: Insight Molecular Diagnostics Q2 2025 reveals strategic advancements - Investing.com Canada
Insight Molecular Diagnostics Reports Q2 Loss of $9.7 Million - AInvest
IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx L - GuruFocus
In Insight Molecular Diagnostics Inc. Announces Graftassuredx Launch - MarketScreener
IMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference - 富途牛牛
Insight Molecular Diagnostics Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView
Insight Molecular Diagnostics Inc.Common Stock (Nasdaq:IMDX) Stock Quote - FinancialContent
Molecular Diagnostics Market Overview: Growth Factors to 2035 - MarketReports.us
PCR Molecular Diagnostics Market Global Forecast 2025–2032: Sector-Wise Insights - newstrail.com
Insight Molecular Diagnostics Inc. shares rise 8.81% premarket after QIAGEN's solid Q2 2025 results. - AInvest
iMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference - The Manila Times
iMDx to Release Second Quarter 2025 Results on August 11, - GlobeNewswire
iMDx Announces Two Major Investor Events: Q2 Earnings and Needham Conference Back-to-Back - Stock Titan
Diagnostic Contract Manufacturing Market Forecast 2025–2034: Key Metrics and Strategic Insights - WhaTech
IMDX World Transplant Congress Late-Breaking Data - GlobeNewswire
Revolutionary Transplant Test Achieves 79% Accuracy, Nearly Doubles Industry Standard in Detecting Organ Rejection - Stock Titan
U.S., Europe, and Asia Pacific Molecular Diagnostics Market - openPR.com
iMDx to Host Virtual KOL Event to Discuss its In-House - GlobeNewswire
Vanderbilt Professor Reveals Game-Changing In-House Kidney Transplant Testing Technology at Expert Event - Stock Titan
Analysts Are Bullish on Top Healthcare Stocks: ProMIS Neurosciences (PMN), Bruker (BRKR) - The Globe and Mail
Insight Molecular Diagnostics Inc. shares fall 3.16% intraday as ImmunoPrecise Antibodies Ltd. announces new findings. - AInvest
Insight Molecular Diagnostics Inc. shares rise 5.32% premarket after Seegene unveils new diagnostic system and data analytics platform. - AInvest
Insight Molecular Diagnostics Insiders Increase Holdings Amidst Bullish Bets - AInvest
Insight Molecular Diagnostics Insiders Placed Bullish Bets Worth US$2.82m - Yahoo Finance
U.S. In Vitro Diagnostics (IVD) Market and Competition - GlobeNewswire
U.S. In Vitro Diagnostics (IVD) Market and Competition Insights 2025-2034Next-Gen Genomic Tools and Decentralized Testing to Transform U.S. Diagnostics Landscape - Yahoo.co
Clinical Laboratory Services Market Expanding with Diagnostic Testing Growth and Automation Advancements - newstrail.com
Sepsis Diagnostics Market: Global Industry Overview, Trends, Challenges, and Regional Insights - PharmiWeb.com
Insight Molecular Diagnostics Inc. shares rise 1.24% intraday after Agilent Technologies and Oxford BioDynamics host webinar on 3D genomic biomarker discovery. - AInvest
Proteinase K Market Grows Amid Rising Demand for Molecular Research and Diagnostics - newstrail.com
Companion Diagnostic Technologies Market Watch: Strategic Forecasts Amid Rising Economic Volatility - newstrail.com
IVD Contract Manufacturing Services Market Watch: Strategic Forecasts Amid Rising Economic Volatility - newstrail.com
Insight Molecular Diagnostics Inc Stock (IMDX) Financials Data
There is no financial data for Insight Molecular Diagnostics Inc (IMDX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Insight Molecular Diagnostics Inc Stock (IMDX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SMITH PATRICK W | 10% Owner |
Feb 07 '25 |
Buy |
2.05 |
1,077,600 |
2,209,080 |
2,872,671 |
| BROADWOOD PARTNERS, L.P. | 10% Owner |
Feb 06 '25 |
Buy |
2.05 |
5,165,695 |
10,589,675 |
11,410,100 |
| SMITH PATRICK W | 10% Owner |
Jan 31 '25 |
Buy |
2.01 |
890 |
1,789 |
1,795,046 |
| SMITH PATRICK W | 10% Owner |
Feb 04 '25 |
Buy |
2.02 |
25 |
50 |
1,795,071 |
| SMITH PATRICK W | 10% Owner |
Jan 29 '25 |
Buy |
2.01 |
3,880 |
7,799 |
1,793,838 |
| SMITH PATRICK W | 10% Owner |
Jan 30 '25 |
Buy |
2.01 |
318 |
639 |
1,794,156 |
| SMITH PATRICK W | 10% Owner |
Jan 14 '25 |
Buy |
2.15 |
10,386 |
22,323 |
1,789,958 |
| SMITH PATRICK W | 10% Owner |
Jan 13 '25 |
Buy |
2.08 |
5,669 |
11,792 |
1,779,572 |
| SMITH PATRICK W | 10% Owner |
Dec 26 '24 |
Buy |
2.13 |
90,219 |
192,166 |
1,773,903 |
| Arno Andrew | Director |
Dec 26 '24 |
Buy |
2.11 |
12,500 |
26,350 |
81,554 |
4.05%
1.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):